{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:24Z","timestamp":1791489624350,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":246,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101429","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:11:46Z","timestamp":1790122306000},"page":"101429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-1224","authenticated-orcid":false,"given":"Baha","family":"Sharaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2937-7052","authenticated-orcid":false,"given":"Mohammad","family":"Alzoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qutaiba","family":"Jawarneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameen","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameed","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinan Bani","family":"Ata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batool","family":"Ajlouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rnad","family":"Khader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Jaffal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhaib","family":"Khater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharif","family":"Jehad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-6051","authenticated-orcid":false,"given":"Hikmat","family":"Abdel-Razeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4905","key":"10.1016\/j.ctarc.2026.101429_bib0001","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101429_bib0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101429_bib0003","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101429_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Five-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in HER2-positive breast cancer (TRAIN-2): a randomized, phase 3 trial","volume":"8","author":"van der Voort","year":"2022","journal-title":"JAMa Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101429_bib0005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.21037\/atm-22-4030","article-title":"Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: a systematic review and meta-analysis","volume":"11","author":"Zhu","year":"2023","journal-title":"Ann. Transl. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101429_bib0006","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3390\/jcm15062217","article-title":"Real-world outcomes of neoadjuvant dual blockade in HER2-positive breast cancer: the role of tumor biology and pCR","volume":"15","author":"Bayramgil","year":"2026","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2026.101429_bib0007","first-page":"1","article-title":"Bridging clinical trials to real-world clinical practice: TCHP neoadjuvant therapy outcomes in HER2-positive breast cancer","volume":"18","author":"Sharaf","year":"2026","journal-title":"Breast Cancer (Dove Med. Press)"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101429_bib0008","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant chemotherapy regimens in patients with HER2-positive early breast cancer (TRYPHAENA): a randomised phase II study","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101429_bib0009","first-page":"59","article-title":"Dual anti-HER2 therapy vs trastuzumab alone with neoadjuvant anthracycline and taxane in HER2-positive early-stage breast cancer: real-world insights","volume":"19","author":"Sharaf","year":"2025","journal-title":"Biol.: Target. Ther."},{"issue":"9938","key":"10.1016\/j.ctarc.2026.101429_bib0010","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101429_bib0011","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101429_bib0012","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ctarc.2026.101429_bib0013","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101429_bib0014","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm. Stat."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101429_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat. Sci."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101429_bib0016","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101429_bib0017","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO-25-02176","article-title":"Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive breast cancer: the randomized noninferiority phase III neoCARHP trial","volume":"44","author":"Gao","year":"2026","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101429_bib0018","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"41","key":"10.1016\/j.ctarc.2026.101429_bib0019","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart. J."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101429_bib0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101429_bib0021","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/s41416-023-02426-4","article-title":"Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level","volume":"129","author":"Alsaleem","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101429_bib0022","first-page":"597","article-title":"Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy","volume":"176","author":"Shamai","year":"2019","journal-title":"Breast. Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101429_bib0023","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer (DESTINY-Breast05)","volume":"394","author":"Loibl","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101429_bib0024","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE)","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101429_bib0025","first-page":"11","article-title":"Cost-effectiveness of docetaxel\/carboplatin\/trastuzumab versus anthracycline-based regimens in HER2-positive breast cancer","volume":"19","author":"Wu","year":"2021","journal-title":"Cost. Eff. Resour. Alloc."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101429_bib0026","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101429_bib0027","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101429_bib0028","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3390\/cancers14112596","article-title":"BERENICE final analysis: cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer","volume":"14","author":"Swain","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101429_bib0029","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer (APHINITY)","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101429_bib0030","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1200\/JCO.2005.02.6914","article-title":"Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors","volume":"24","author":"Guarneri","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"9 Suppl","key":"10.1016\/j.ctarc.2026.101429_bib0031","article-title":"Efficacy of dose-dense and anthracycline-free regimens in neoadjuvant chemotherapy of HER2-positive breast cancer: a single-center matched-cohort study","volume":"84","author":"Kovalenko","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101429_bib0032","first-page":"371","article-title":"Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study","volume":"212","author":"Helgeson","year":"2025","journal-title":"Breast. Cancer Res. Treat."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101429_bib0033","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.3390\/cancers17193190","article-title":"Oncologic outcomes and safety of neoadjuvant anthracycline versus anthracycline-free regimens in HER2-positive early breast cancer in a Colombian cancer center","volume":"17","author":"S\u00e1nchez-Mora\u00f1o","year":"2025","journal-title":"Cancers. (Basel)"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101429_bib0034","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.seminoncol.2020.07.007","article-title":"Risk-based approaches for optimizing treatment in HER2-positive early stage breast cancer","volume":"47","author":"Chiec","year":"2020","journal-title":"Semin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:39:08Z","timestamp":1791488348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"alternative-id":["S2468294226003394"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101429","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anthracycline-free versus anthracycline-based neoadjuvant therapy in HER2-positive breast cancer: A Propensity score-matched real-world study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101429"}}